Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Last updated: May 9, 2022
Sponsor: Sheba Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pulmonary Fibrosis

Treatment

N/A

Clinical Study ID

NCT04392726
SHEBA-20-7020-20-SMC-LL-CTIL
  • Ages 18-85
  • All Genders

Study Summary

The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims:

  1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping.

  2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. suspected or known DPLD
  2. referred to DPLD observation

Exclusion

Exclusion Criteria:

  1. other lung related diseases

Study Design

Total Participants: 30
Study Start date:
August 01, 2020
Estimated Completion Date:
January 30, 2024

Connect with a study center

  • Sheba Medical Center

    Ramat Gan,
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.